COMPANY:

Paige

"Tempus AI...today announced the acquisition of Paige, an AI company specializing in digital pathology. The acquisition allows Tempus to grow its dataset, expand its experienced technical team, and establish a strong footprint in digital pathology with an industry leading technology portfolio."

"At the Radiological Society of North America's (RSNA) 109th Scientific Assembly and Annual Meeting, Paige...announced it has teamed up with Nuance...to create the largest digital consultation network in pathology. This secure best-in-class platform will revolutionize collaboration among U.S. pathologists, making consultations faster and more efficient."

"Paige...announced today that the U.S Food and Drug Administration (FDA) has granted Breakthrough Device Designation for Paige Lymph Node1, an AI application used to detect breast cancer metastases in lymph node tissue. Paige Lymph Node is the first AI application of its kind to receive Breakthrough Device Designation from the FDA."

"Paige...has joined forces with Microsoft in the fight against cancer, making headway in their collaboration to transform cancer diagnosis and patient care by building the world’s largest image-based artificial intelligence (AI) models for digital pathology and oncology."

"Paige...announced a collaboration with Ohio State University Wexner Medical Center (OSWMC) and its affiliated community hospitals. They will conduct a multi-arm clinical utility and health economics study to measure the accuracy, efficiency and cost-savings impact of using AI tools in diagnosing cancer in a community hospital setting. OSWMC will utilize the Paige Prostate Suite, including Paige Prostate Detect, the only FDA approved AI-powered pathology algorithm, to assess the differences between diagnoses made with and without the use of AI."

"Paige...and University of Florida College of Medicine – Jacksonville today announced the Department of Pathology and Laboratory Medicine’s decision to adopt Paige’s full portfolio of AI offerings for their lab, including the Paige Prostate Suite and Paige Breast Suite."

"Paige...announced a new AI-based digital assay to support pathologists in the detection and diagnosis of microsatellite instability (MSI) status in colon cancers. Paige Colon MSI operates on whole slide images of hematoxylin and eosin (H&E)-stained slides alone, offering slide-level classification of MSI status in colon cancer samples* based on morphologies associated with the presence or absence of MSI/MMR phenotype. Paige Colon MSI is a new addition to Paige’s Colon Suite which also includes case and slide-level detection of suspicious regions including invasive carcinoma and high-grade dysplasia."

"Paige...introduced new advanced integration capabilities to the Paige Platform, a holistic web-based solution that enables complete digital pathology workflows and supports the evolving needs of today’s modern lab...With Paige’s flexible platform at the nexus of the digital pathology ecosystem, labs and pathologists can connect their existing and future digital pathology applications into a single environment managed by Paige."

"Paige...announced it is working with Visiopharm...to bring a wider range of AI products to doctors and patients. Visiopharm’s AI applications will be deployed and natively integrated into the Paige Platform to be accessed through FullFolio™, Paige’s AI-powered clinical worklist, and viewed within FullFocus®, Paige’s whole-slide image viewer. This deep integration offers users greater diagnostic efficiency and quality insights when reviewing IHC-stained slides and creates a seamless user experience for Visiopharm’s image analysis applications, to help pathologists deliver faster, more accurate and more reproducible cancer diagnoses."